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activate the STAT3 and SMAD2/3 pathways in NK cells 
and suppress IL-2 induction of cytotoxicity, granzymes 
A and B release, perforin expression, and IFNγ secretion. 
Lenalidomide blocks IL-6 and TGFβ1 activation of these 
signaling pathways and inhibits their suppression of NK 
cells. Neuroblastoma cells in NOD/SCID mice exhibit 
activated STAT3 and SMAD2/3 pathways. Their growth is 
most effectively inhibited by co-injected peripheral blood 
mononuclear cells (PBMC) containing NK cells when mice 
are treated with both ch14.18 and lenalidomide.
Conclusion Immunotherapy with anti-tumor cell anti-
bodies may be improved by lenalidomide, which enhances 
activation of NK cells and inhibits their suppression by 
IL-6 and TGFβ1.
Keywords Neuroblastoma · NK cells · ADCC · 
Lenalidomide · IL-6 · TGFβ1
Introduction
Addition of anti-disialoganglioside (GD2) chimeric mAb 
ch14.18, IL-2, and GM-CSF immunotherapy to 13-cis-reti-
noic acid improved event-free survival (EFS) for patients 
with high-risk neuroblastoma, but approximately 40 % still 
relapsed during or after this therapy [1]. An immunosup-
pressive tumor microenvironment could negatively impact 
the anti-tumor cell activity of antibody therapy that is 
largely reliant upon antibody-dependent cellular cytotox-
icity (ADCC) mediated by natural killer (NK) cells. Our 
gene expression analyses of high-risk, metastatic neuro-
blastomas without MYCN gene amplification using Affy-
metrix® microarrays and TaqMan® low-density arrays 
revealed that high expression of genes related to inflam-
mation, including IL-6, IL-6R, and TGFβ1, was associated 
Abstract 
Background Treatment for children with high-risk neuro-
blastoma with anti-disialoganglioside mAb ch14.18, IL-2, 
and GM-CSF plus 13-cis-retinoic acid after myeloablative 
chemotherapy improves survival, but 40 % of patients still 
relapse during or after this therapy. The microenvironment 
of high-risk neuroblastoma tumors includes macrophages, 
IL-6, and TGFβ1. We hypothesized that this microenviron-
ment suppresses anti-tumor functions of natural killer (NK) 
cells and that lenalidomide, an immune-modulating drug, 
could overcome suppression.
Methods Purified NK cells were cultured with IL-2, neu-
roblastoma/monocyte-conditioned culture medium (CM), 
IL-6, TGFβ1, and lenalidomide in various combinations 
and then characterized using cytotoxicity (direct and anti-
body-dependent cell-mediated cytotoxicity), cytokine, flow 
cytometry, and Western blotting assays. Anti-tumor activity 
of NK cells with lenalidomide, ch14.18, or both was evalu-
ated with a xenograft model of neuroblastoma.
Results CM from neuroblastoma/monocyte co-cultures 
contains IL-6 and TGFβ1 that suppress IL-2 activation of 
NK cell cytotoxicity and IFNγ secretion. IL-6 and TGFβ1 
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with a poor 5-year EFS [2–4]. Furthermore, we found that 
high-risk primary neuroblastoma tumors contain CD68+ 
tumor-associated monocytes/macrophages (TAMs) produc-
ing IL-6 and that bone marrows with neuroblastoma metas-
tases include CD33+ CD14+ monocytic cells, which also 
express IL-6 [3]. Experimentally, we have shown that neu-
roblastoma cells stimulate blood monocytes to secrete IL-6 
and that TAMs stimulate the growth of neuroblastoma cells 
in NOD/SCID mice, at least partially via IL-6 secretion [3].
IL-6, which induces activation of the STAT3 signaling 
pathway, has not been definitively shown to affect the func-
tion of human NK cells. Treatment for patients with recom-
binant human IL-6 has been reported to suppress the ability 
of their peripheral blood mononuclear cells (PBMC) to kill 
K562 cells in vitro [5]. Although K562 cells are sensitive to 
NK cell cytotoxicity, this study did not demonstrate a direct 
effect of IL-6 upon NK cells or any other possible mecha-
nism [5]. The potential importance of STAT3 pathway acti-
vation in suppressing NK cell cytotoxicity is supported by 
experiments showing that NK cells from tumor-bearing 
mice with induced ablation of STAT3 signaling are more 
cytotoxic against T cell lymphoma YAC-1 cells, which are 
NK cell-sensitive, than those from tumor-bearing mice with 
wild-type STAT3 [6].
TGFβ1 activates the SMAD2/3 signaling pathway 
in human NK cells, which results in the suppression of 
ADCC and secretion of IFNγ, TNFα, and GM-CSF in vitro 
[7–9]. Culture of blood NK cells with TGFβ1 decreases 
the expression of CD16 after 24 h [10, 11]. NK cells from 
patients with glioblastoma, lung, and colorectal cancer 
have decreased the expression of the activating immuno-
receptor NKG2D, and TGFβ1 in serum and cerebrospinal 
fluid is responsible for this down-regulation [12, 13].
Based upon the above observations, we hypothesized 
that IL-6 and TGFβ1 in the neuroblastoma microenviron-
ment may contribute to the failure of treatment with mAb 
ch14.18 by suppressing anti-tumor functions of NK cells. 
Using purified NK cells, we found that anti-tumor NK cell 
functions induced in vitro by IL-2, including direct cyto-
toxicity, ADCC, and IFNγ secretion, are suppressed by 
conditioned medium (CM) from neuroblastoma/monocyte 
co-cultures that contain IL-6 and TGFβ1 and that suppres-
sion is removed by the depletion of these cytokines from 
the CM. Additionally, these recombinant cytokines sup-
pressed IL-2 activation of NK cells.
Lenalidomide is an immune-modulating drug that acti-
vates T cells to secrete IL-2, which in turn activates NK 
cell cytotoxicity and ADCC [14, 15]. Clinical trials in 
children and adults demonstrated a greater number of NK 
cells and increased cytotoxicity, decreased T regulatory 
cells, and increased secretion of IL-2, IL-15, and GM-CSF 
after 21 days of lenalidomide treatment [16, 17]. Preclini-
cal in vitro data have shown that lenalidomide can enhance 
ADCC mediated by human NK cells with rituximab (anti-
CD20) against lymphoma and chronic lymphocytic leu-
kemia cells [18–20], with SGN-40 (anti-CD40) against 
multiple myeloma and chronic lymphocytic leukemia 
cells [21, 22], and with trastuzumab (anti-HER2/neu) and 
cetuximab (anti-EGFR) against solid tumor cell lines [23]. 
Because of these clinical and preclinical effects, we hypoth-
esized that lenalidomide also could prevent the suppression 
of IL-2 activation of NK cells by neuroblastoma/monocyte 
CM, IL-6, and TGFβ1. Indeed, we show that lenalidomide 
blocks the activation of STAT3 and SMAD2/3 signaling 
pathways and prevents the suppression of NK cell activa-
tion in vitro. Further, NK cells among PBMC that are co-
injected with neuroblastoma cells into NOD/SCID mice 
have the greatest anti-tumor effect when mice are treated 
with both lenalidomide and mAb ch14.18.
Materials and methods
For additional details on “Materials and methods,” see Sup-
plemental Methods.
Reagents
Details for reagents are provided in Supplemental Meth-
ods. Anti-GD2 chimeric mAb ch14.18 was provided by 
the National Cancer Institute-Frederick. Lenalidomide was 
provided by Celgene and was dissolved in dimethyl sul-
foxide (final DMSO concentration for in vitro and in vivo 
experiments was 0.03 and 5 %, respectively).
Neuroblastoma cell lines and tumors
The CHLA-255 parent cell line, the firefly luciferase (Fluc) 
and humanized Renilla luciferase (hRluc) transfected 
CHLA-255 cell lines, and the LA–N-1 cell line were cul-
tured in IMDM with 15 % FBS. Primary untreated tumors 
from patients with high-risk, stage 4 (metastatic) neuro-
blastoma were obtained from patients enrolled and con-
sented in therapeutic and biology protocols of the Chil-
dren’s Oncology Group (COG).
NK cells, monocytes, and cell culture
PBMC were isolated from blood of normal adult donors by 
density separation using Ficoll-Hypaque [24]. NK cells and 
monocytes were isolated from PBMC by negative selection 
using a NK Cell Isolation Kit or a Monocyte Cell Isolation 
Kit, an LS Column, and a MidiMACS™ Separator accord-
ing to the manufacturer’s protocol (Miltenyi Biotec). Puri-
fied NK cells (CD56+ CD16+ CD3−) were >95 %, and 
purified monocytes (CD14+) were >95 %. NK cells were 
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removed from PBMC by positive selection using CD56 
MicroBeads and the column and separator mentioned 
above (CD56+ was <0.02 %; Fig. 6 legend). Purified 
NK cells (1 × 104) were cultured in 96-well black Costar 
plates (Corning, Inc.) in 100 μl RPMI-1640 (Invitrogen) 
with 15 % FBS in the presence of IL-2 (10 ng/ml). CM for 
testing with NK cells was generated with 72-h cultures of 
monocytes (106/ml), CHLA-255-Fluc neuroblastoma cells 
(106/ml), or CHLA-255-Fluc/monocytes together (106/ml 
of each cell type) in IMDM and 15 % FBS. Blood from 
normal adult donors was obtained in accordance with a 
protocol approved by the Committee on Clinical Investiga-
tion (CCI) at Children’s Hospital Los Angeles.
Cytotoxicity assay
For cytotoxicity assays, two neuroblastoma cell lines (LA–
N-1 and CHLA-255-Fluc) were labeled with calcein-AM 
for 30 min [25] and then 5 × 103 tumor cells were added to 
NK cells that had been cultured for 72 h at an effector-to-
target (E:T) cell ratio of 2:1 with or without mAb ch14.18 
(0.1 μg/ml). These cells were then co-incubated for 6 h at 
37 °C, and surviving tumor cells were quantified as calcein-
containing cells with a digital imaging microscopy system 
(DIMSCAN), a fluorescence-based multi-well assay, as 
previously described [25].
TaqMan® low-density array (TLDA) assays, flow 
cytometry, cytometric bead array (CBA), Luminex®, 
ELISA assays, and Western blotting
Details are provided in Supplemental Methods.
Murine model of neuroblastoma
Female NOD/SCID mice that were 4 weeks old were 
purchased from The Jackson Laboratory. Rat anti-mouse 
CD122/IL-2Rβ (200 mg/mouse) was injected intraperito-
neally 1 day before tumor cell injection to eliminate resid-
ual murine NK cells [26]. CHLA-255-Fluc neuroblastoma 
cells and human PBMC were co-injected subcutaneously 
near both shoulders in 25 % (v/v) BD Matrigel™ Matrix 
Growth Factor Reduced (BD Biosciences). Tumor growth 
was assessed by bioluminescence imaging using a Xeno-
gen IVIS® 100 instrument. Animal experiments were done 
in accordance with a protocol approved by the Institutional 
Animal Care and Usage Committee of Children’s Hospital 
Los Angeles.
Statistical analysis
Data were analyzed using Stata statistical software (version 
11.2) and are represented as mean ± SD unless otherwise 
stated. Two-tailed Student’s independent sample t test was 
performed to determine the significance of the observed 
differences. A P value of <0.05 was considered significant. 
Analysis of tumor bioluminescence data transformed the 
average photon flux of two tumors for each mouse using 
the log (flux + 1) transformation and then calculated the 
area under the growth curve (AUC). The AUC values were 
used in the analysis to compare differences in tumor pho-
ton flux between treatment groups. Mouse survival time is 
defined as the length of time (in days) from the tumor cell 
injection date until the mouse is killed due to tumor size 
(1.5 cm diameter) or end of the study. Linear regression 
was utilized to determine any differences in the AUC due 
to cell type (PBMC versus PBMC-depleted NK cells) and 
treatment groups (lenalidomide, ch14.18, or lenalidomide 
with ch14.18). Similarly, survival time was evaluated using 
censored normal regression.
Results
High level expression of mononuclear 
phagocyte-associated genes, IL-6, IL-6R, IL-10, 
and TGFβ1 in neuroblastoma tumors from patients
Gene expression of MYCN-amplified and non-amplified 
stage 4 (metastatic) neuroblastoma tumors and cell lines 
was assessed using TLDA assays. Monocyte-associated 
genes such as CD14, CD16, CD68, and HMOX1 as well 
as IL-6, IL-6R, and IL-10 were expressed by tumors, 
whereas their expression was significantly lower in cell 
lines (Fig. 1). In contrast, both tumors and cell lines 
expressed TGFβ1 at high and near-equal levels, and genes 
that are directly and indirectly regulated by TGFβ1 (i.e., 
TBX21/TBET and IFNγ) were weakly expressed in tumors 
(Fig. 1). IL-2, IL-15, IL-12A/p35, and IL-12B/p40, which 
are important for NK cell proliferation, differentiation, 
and activation [27], were weakly expressed by tumors and 
cell lines. Comparing the expression of IL-6, IL-10, and 
TGFβ1 to that of IL-2, IL-15, IL-12A, IL-12B, and IFNγ 
demonstrated 5- to 42-fold greater levels of the former 
than the latter (Fig. 1). These data suggest that neuroblas-
toma tumors are rich in potentially immunosuppressive 
cytokines (IL-6 and TGFβ1), but not in cytokines that sup-
port NK cell proliferation, differentiation, and activation 
(IL-2, IL-15, IL-12A, and IL-12B).
Neuroblastoma cell line cultures release TGFβ1 
and neuroblastoma/monocyte co-cultures release TGFβ1, 
IL-6, and IL-10
TGFβ1 was released into the culture medium by 12 of 15 
well-characterized neuroblastoma cell lines [28–31], as 
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assessed by ELISA analysis of CM after 72 h (Fig. 2a). 
Culture of purified monocytes with 72-h tumor cell line 
CM showed that 6 of 15 CM also stimulated the secre-
tion of TGFβ1 by monocytes after 24 h (data not shown). 
In contrast, IL-6 was not released by neuroblastoma cell 
lines (data not shown and Supplemental Figure 1); how-
ever, 72-h CM of 8 of 15 neuroblastoma cell lines stim-
ulated monocytes to secrete IL-6 after 24 h (Fig. 2b). 
IL-10 was minimally secreted by CHLA-255-Fluc cells 
or monocytes alone but was secreted by co-cultured 
cells (Supplemental Figure 1). CHLA-255-Fluc cells 
and monocytes alone or co-cultured secreted <25 pg/ml 
of IFNγ, IL-2, IL-15, IL-12p70 (functional heterodimer 
of IL-12p35 and IL-12p40 subunits) (Supplemental Fig-
ure 1). Thus, the profile of cytokines released by neuro-
blastoma cell lines alone, by monocytes cultured in tumor 
cell CM, or by neuroblastoma/monocyte co-cultures is 
comparable to the profile of cytokine gene expression in 
primary untreated tumors.
Suppression of IL-2 induction of NK cell cytotoxicity 
and IFNγ secretion by IL-6 and TGFβ1 in neuroblastoma/
monocyte-conditioned medium is prevented 
by lenalidomide
Based upon the release of TGFβ1 by tumor cells and of 
IL-6 and TGFβ1 by monocytes cultured in tumor cell CM 
and upon the possibility that these cytokines could sup-
press activation of NK cells [5, 7], we determined the 
effect of neuroblastoma/monocyte co-culture CM on IL-2 
activation of purified NK cells using cytotoxicity and 
IFNγ secretion as end points (Fig. 2c–e). Indeed, 50 % 
CM (volume/volume), which contained IL-6 (560 pg/ml) 
and TGFβ1 (410 pg/ml), significantly suppressed the acti-
vation of NK cells for direct cytotoxicity and ADCC and 
for the secretion of IFNγ (Fig. 2c–e). Although the neuro-
blastoma/monocyte CM contained IL-6 and TGFβ1, these 
cytokines were increased further in cultures of NK cells 
and IL-2 (Fig. 2e).
Fig. 1  Expression of monocyte/macrophage and cytokine genes in 
neuroblastoma tumors and cell lines. Expression of genes in primary 
untreated high-risk, metastatic neuroblastomas (n = 38) and in neu-
roblastoma cell lines (n = 23) was quantified with a TaqMan® low-
density array assay. Normalized expression (ΔCT) of monocyte/
macrophage-associated genes (HMOX1, CD14, CD68, CX3CR1, and 
CD16b), of IL-10, IL-6, IL-6R, TGFβ1, and TBX21, and of NK cell 
growth, survival, and activation genes (IL-2, IL-15, IL-12A, IL-12B, 
and IFNγ) are shown. Fold change in gene expression by tumors as 
compared to cell lines was calculated using 2(ΔCT of Tumor − ΔCT of Cell 
lines)
. A comparison of expression of IL-6, IL-10, and TGFβ1 versus 
IFNγ, IL-2, IL-15, IL-12A, and IL-12B in neuroblastoma tumors is 
shown in the lower table
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Fig. 2  Suppression of IL-2 induction of NK cell direct cytotoxicity, 
ADCC, and IFNγ secretion by neuroblastoma/monocyte-conditioned 
medium is prevented by lenalidomide. a Fifteen neuroblastoma cell 
lines (5 × 105 cells/ml) were cultured for 72 h, and then, the total 
TGFβ1 was quantified in the CM by ELISA (mean ± SD for 3 rep-
licate cultures). b Purified monocytes (5 × 105 cells/ml) were cul-
tured for 24 h with CM generated after 72 h by fifteen neuroblas-
toma cell lines (5 × 105 cells/ml), and then IL-6 was quantified in 
monocyte supernatants by ELISA (mean ± SD for 3 replicate cul-
tures). Cell lines alone did not secrete IL-6. The t test P values for 
medium alone versus CM *P < 0.05; **P < 0.01. c, d NK cells 
isolated from PBMC were cultured (1 × 104 cells/0.1 ml/well) for 
72 h with IL-2 alone (10 ng/ml), with added CM (50 % v/v) from 
monocytes (M), CHLA-255-Fluc neuroblastoma cells (NB), or neu-
roblastoma/monocyte co-culture (N + M CM), and with lenalidomide 
(10 μM) as indicated, and then direct cytotoxicity and ADCC (E:T 
ratio = 2:1) with ch14.18 (0.1 μg/ml) were quantified after 6 h of co-
culture with CHLA-255-Fluc neuroblastoma cells using the calcein-
AM/DIMSCAN assay (mean ± SD for 8 replicate cultures for each 
condition). The M, NB, and M + NB CMs had 312, 159, and 412 pg/
ml TGFβ1; 11, 37, and 556 pg/ml IL-6; and 12, 14, and 13 pg/ml 
of IFNγ, respectively. e IFNγ, IL-6, and TGFβ1 were quantified by 
ELISA in the culture media from these same NK cell cultures at 72 h, 
and the amount of each cytokine contributed by NK cells was calcu-
lated (NK cytokine = total cytokine − CM cytokine ÷ 2). Confirma-
tory results were obtained from 1 additional experiment. The t test P 
values *P < 0.05; **P < 0.01
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Lenalidomide has been reported to activate NK cells 
[14, 15], and we confirmed this using clinically achiev-
able doses (Supplemental Figure 2). Based upon this strong 
activity, we hypothesized that neuroblastoma/monocyte 
suppression of NK cell activation could be overcome by 
lenalidomide. As shown in Fig. 2c–e, inclusion of lenalido-
mide in cultures containing 50 % neuroblastoma/monocyte 
CM prevented the suppression of IL-2-induced direct cyto-
toxicity, ADCC, and IFNγ secretion. Inclusion of lenalido-
mide also suppressed CM induction of NK cell secretion of 
IL-6 and TGFβ1 (Fig. 2e).
To determine whether IL-6 and TGFβ1 were responsible 
for the suppression of NK cell cytotoxicity and ADCC, they 
were depleted from the neuroblastoma/monocyte CM with 
anti-cytokine antibodies (Supplemental Figure 3). Com-
bined depletion of IL-6 and TGFβ1 from the CM with anti-
cytokine antibodies removed inhibition of IL-2 activation 
of NK cells for direct cytotoxicity and ADCC (Supplemen-
tal Figure 3). These data along with the gene expression 
profile of neuroblastoma tumors and cytokines released 
by neuroblastoma and monocyte co-cultures suggest that 
neuroblastoma/monocyte interactions generate a cytokine 
milieu that suppresses NK cell anti-tumor functions.
Suppression of IL-2 induction of NK cell cytotoxicity 
and IFNγ secretion by recombinant IL-6 and TGFβ1 is 
prevented by lenalidomide
Since the suppression of NK cell activation by neuro-
blastoma/monocyte CM was likely due to IL-6 [5] and/
or TGFβ1 [7], we next tested these cytokines alone and 
with lenalidomide to determine the effects upon NK cell 
activation. Purified NK cells were cultured for 72 h with 
IL-2 and IL-6 or TGFβ1 without or with lenalidomide 
and then tested for direct cytotoxicity, ADCC, and IFNγ 
secretion. NK cells cultured with IL-6 or TGFβ1 medi-
ated less direct cytotoxicity and ADCC and secreted 
less IFNγ than those cultured with IL-2 alone (Fig. 3). 
However, the suppression of NK cell cytotoxicity func-
tions by these cytokines was prevented by the addition 
of lenalidomide to the cultures (Fig. 3). Similarly, the 
suppression of IFNγ secretion by NK cells was largely 
Fig. 3  Suppression of IL-2 induction of NK cell direct cytotoxicity, 
ADCC, and IFNγ secretion by IL-6 and TGFβ1 is prevented by lena-
lidomide. a, b Purified NK cells (1 × 104 cells/0.1 ml/well) were cul-
tured for 72 h with IL-2 alone (10 ng/ml) or with added IL-6 (10 ng/
ml) and lenalidomide as indicated, and then NK cell-mediated cyto-
toxicity and ADCC (E:T ratio = 2:1) with ch14.18 (0.1 μg/ml) were 
quantified after 6 h of co-culture with CHLA-255-Fluc cells with the 
calcein-AM/DIMSCAN assay (mean ± SD for 8 replicate cultures 
for each condition). Confirmatory results were obtained from 3 addi-
tional experiments. c NK cells (5 × 105/ml) were cultured for 24 h 
with IL-2 alone (10 ng/ml) or with added IL-6 (10 ng/ml) and lenalid-
omide as indicated, and then IFNγ was quantified in the medium by 
ELISA (mean ± SD for 3 replicate cultures for each condition). Con-
firmatory results were obtained with 2 additional experiments. d, e 
NK cells (1 × 104 cells/0.1 ml/well) were cultured for 72 h with IL-2 
alone (10 ng/ml) or with added TGFβ1 (10 ng/ml) and lenalidomide 
as indicated, and then NK cell-mediated cytotoxicity and ADCC (E:T 
ratio = 2:1) with ch14.18 (0.1 μg/ml) were quantified after 6 h of co-
culture with CHLA-255-Fluc cells with the calcein-AM/DIMSCAN 
assay (mean ± SD for 8 replicate cultures for each condition). Con-
firmatory results were obtained from 3 additional experiments. f 
NK cells (5 × 105 cells/ml) were cultured for 24 h with IL-2 alone 
(10 ng/ml) or with added TGFβ1 (10 ng/ml) and lenalidomide as 
indicated, and then IFNγ was quantified in the medium by ELISA 
(mean ± SD for 3 replicate cultures for each condition). Confirma-
tory results were obtained with 1 additional experiment. The t test P 
values, no lenalidomide versus lenalidomide *P < 0.05; **P < 0.01
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overcome by lenalidomide (Fig. 3). IL-6, similar to the 
neuroblastoma/monocyte CM (Fig. 2), significantly 
increased NK cell secretion of IL-6, whereas lenalido-
mide prevented this effect (data not shown). TGFβ1, 
in contrast, decreased NK cell secretion of IL-6, and 
this was not altered by lenalidomide (data not shown). 
Thus, anti-tumor functions of NK cells are suppressed 
by IL-6 and TGFβ1, and this is largely prevented by 
lenalidomide.
Suppression of NK cell functions contributing 
to cytotoxicity by recombinant IL-6 and TGFβ1 is 
prevented by lenalidomide
Effects of IL-6 and TGFβ1 on NK cell functions that 
contribute to cytotoxicity without and with lenalidomide 
were determined. When IL-6 was added to NK cells cul-
tured for 72 h with IL-2, it did not affect the expression of 
cell surface NKG2D, DNAM-1, NKp46, CD16, adhesion 
molecule CD56, or degranulation marker CD107a (Fig. 4a 
and data not shown). However, IL-6 did suppress the 
release of granzymes A and B and expression of perforin 
by purified NK cells (Fig. 4b, c). Lenalidomide, in the 
presence of IL-6, did not increase the expression of the 
evaluated cell surface molecules with exception of CD56 
(Fig. 4a and data not shown), but it did prevent the sup-
pression of granzymes A and B release and of perforin 
expression (Fig. 4b, c).
When TGFβ1 was added to NK cells cultured for 72 h 
with IL-2, it suppressed the expression of cell surface 
NKG2D, DNAM-1, NKp46, CD16, CD56, and CD107a 
as well as release of granzymes A and B and expression of 
perforin (Fig. 5a–c; Supplemental Figure 4). Lenalidomide 
did not prevent TGFβ1 suppression of NKG2D, DNAM-1, 
NKp46, or CD16 but did prevent its inhibitory effect upon 
expression of CD56 and CD107a, release of granzymes A 
and B, and expression of perforin (Fig. 5a–c; Supplemental 
Figure 4).
Fig. 4  Suppression of NK cell cytotoxicity-related functions and 
activation of STAT3 by IL-6 is prevented by lenalidomide. a Purified 
NK cells (5 × 105 cells/ml) were cultured for 72 h with IL-2 alone 
(10 ng/ml) or with addition of IL-6 (10 ng/ml) and lenalidomide as 
indicated, and then the expression of DNAM-1 was evaluated with 
flow cytometry. A similar pattern of little or no effect was observed 
for NKG2D, NKp46, CD16, CD56, and CD107a (data not shown). 
b NK cells (5 × 105 cells/ml) were cultured for 72 h with IL-2 alone 
(10 ng/ml) or with added IL-6 (10 ng/ml) and lenalidomide as indi-
cated, and then granzymes A and B were quantified in the CM with 
the CBA assay (mean ± SD for 3 replicate cultures for each condi-
tion). Confirmatory results were obtained with 2 additional experi-
ments. c NK cells (5 × 105 cells/ml) were cultured for 72 h with IL-2 
alone (10 ng/ml) or with added IL-6 (10 ng/ml) and lenalidomide, 
and then intracellular perforin was analyzed by flow cytometry. The 
percent of NK cells expressing perforin in the different culture con-
ditions is shown (mean ± SD for 3 replicate cultures for each con-
dition). Confirmatory results were obtained with 2 additional experi-
ments. d NK cells were preincubated (20 min) with lenalidomide at 
the indicated concentrations, treated with IL-6 (10 ng/ml) or IL-6 
plus sIL-6R (25 ng/ml) for 30 min, and then lysed for the analysis of 
phosphorylated STAT3 by Western blotting. Densitometry confirmed 
that lenalidomide inhibited phosphorylation of STAT3. Confirmatory 
results were obtained with 1 additional experiment. The t test P val-
ues *P < 0.05; **P < 0.01
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IL-6-induced STAT3 phosphorylation and TGFβ1-induced 
SMAD2/3 phosphorylation in NK cells are inhibited 
by lenalidomide
STAT3 was phosphorylated in purified NK cells follow-
ing stimulation with IL-6 alone or combined with sIL-6R, 
as assessed by Western blotting (Fig. 4d). To determine 
whether lenalidomide could block IL-6 stimulation of 
STAT3 phosphorylation, NK cells were treated for 20 min 
with lenalidomide (0.1, 1, and 10 μM), followed by treat-
ment for another 30 min with IL-6 (10 ng/ml) alone or with 
sIL-6R (25 ng/ml). Lenalidomide significantly inhibited 
IL-6- and IL-6/sIL-6R-induced STAT3 phosphorylation 
in NK cells (Fig. 4d). This suggests that the inhibition of 
STAT3 phosphorylation by lenalidomide may be one mech-
anism, whereby it blocks the inhibitory effect of IL-6 on 
NK cell activation by IL-2.
To test the effect of lenalidomide upon TGFβ1-
induced signaling, NK cells were treated for 20 min with 
lenalidomide (0.1, 1, and 10 μM) followed by treatment 
for another 20 min with TGFβ1 (10 ng/ml). Western blot-
ting showed that TGFβ1 induced the phosphorylation of 
SMAD2/3 and SMAD1/5/8 and that lenalidomide inhibited 
the phosphorylation of SMAD2/3 but not of SMAD1/5/8 
(Fig. 5d). The inhibitory effect of lenalidomide was fur-
ther confirmed by fluorescence microscopy with anti-phos-
pho-SMAD2/3, which demonstrated markedly decreased 
immunostaining and nuclear translocation (Supplemental 
Figure 5A and 5B).
NK cell anti-neuroblastoma activity with anti-GD2 mAb 
ch14.18 in NOD/SCID mice is enhanced by lenalidomide
A NOD/SCID mouse model of local disease was used in 
which CHLA-255-Fluc neuroblastoma cells (106) were 
co-injected with PBMC (0.25 × 106) in 25 % (v/v) BD 
Matrigel™ Matrix Growth Factor Reduced, which includes 
TGFβ1. In this model, the SMAD2/3 and STAT3 signaling 
Fig. 5  Suppression of NK cell cytotoxicity-related functions and 
activation of SMAD2/3 by TGFβ1 is prevented by lenalidomide. a 
NK cells (5 × 105 cells/ml) were cultured for 72 h with IL-2 alone 
(10 ng/ml) or with added TGFβ1 (10 ng/ml) and lenalidomide as 
indicated, and then the expression of DNAM-1 was evaluated with 
flow cytometry. A similar pattern of suppression was observed for 
NKG2D, NKp46, CD16, CD56, and CD107a (Supplemental Fig-
ure 4). b NK cells (5 × 105 cells/ml) were cultured for 72 h with 
IL-2 alone (10 ng/ml) or with added TGFβ1 (10 ng/ml) and lena-
lidomide as indicated, and then granzymes A and B were quantified 
in the CM with the CBA assay (mean ± SD for 3 replicate cultures 
for each condition). Confirmatory results were obtained from 2 
additional experiments. c NK cells (5 × 105 cells/ml) were cultured 
for 72 h with IL-2 alone (10 ng/ml) or with added TGFβ1 (10 ng/
ml) and lenalidomide, and then intracellular perforin was analyzed 
by flow cytometry. The percent of NK cells expressing perforin in 
the different culture conditions is shown (mean ± SD for 3 repli-
cate experiments for each condition). d NK cells were preincubated 
(20 min) with lenalidomide at the indicated concentrations, treated 
with TGFβ1 (10 ng/ml) for 20 min, and then lysed for the analysis 
of phosphorylated SMAD2/3 by Western blotting. Densitometry con-
firmed that lenalidomide inhibited phosphorylation of SMAD2/3. 
Confirmatory results were obtained with 1 additional experiment. The 
t test P values *P < 0.05; **P < 0.01
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pathways are activated in tumor cells as shown using 
CHLA-255 SMAD2/3 and STAT3 Fluc reporter cell lines, 
and activation is inhibited by lenalidomide (Supplementary 
Figure 6A and 6B). Based on these in vivo data and our 
in vitro experiments, we reasoned that the pathways also 
could be activated in NK cells among the PBMC in vivo 
but that lenalidomide could overcome this and enhance 
NK cell anti-tumor functions. Mice were treated with lena-
lidomide alone, ch14.18 alone, or both together (Fig. 6a). 
After 14 days of treatment, lenalidomide combined with 
ch14.18 most effectively suppressed tumor cell growth 
(AUC) compared to untreated (P < 0.001), lenalidomide 
alone (P = 0.007), or ch14.18 alone (P = 0.011)-treated 
mice (Fig. 6B). Survival time was also longer for the lena-
lidomide plus ch14.18-treated group than for untreated 
(P < 0.0001), lenalidomide-treated (P < 0.0001) or ch14.18-
treated (P < 0.0001) groups (Fig. 6c). When mice receiving 
NK-depleted PBMC were treated with lenalidomide plus 
ch14.18, they had greater tumor growth (P = 0.05) and 
poorer survival (P = 0.006) than the PBMC group (Fig. 6b 
and Supplemental Figure 7). Tumor growth was no dif-
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Fig. 6  NK cells among PBMC that are co-injected with neuroblas-
toma cells into NOD/SCID mice are most effective when mice are 
treated with both lenalidomide and ch14.18. CHLA-255-Fluc neuro-
blastoma cells (106) and PBMC (0.25 × 106; CD3+ 75.3 %; CD3–
CD56+ CD16+ 2.7 %) or NK cell depleted PBMC (PBMC-NK) 
(0.25 × 106; CD3+ 82.6 %; CD3–CD56+ CD16+ 0.02 %) were 
co-injected into NOD/SCID mice near the right and left shoulders 
in 25 % (v/v) BD Matrigel® Matrix Growth Factor Reduced on day 
0. Treatment began on day 1 (after imaging and randomization) with 
lenalidomide alone (50 mg/kg/d intraperitoneal days 1–9 and 12–16), 
ch14.18 alone (15 μg/mouse intravenous days 3, 5, 8, and 12), or 
the combination of lenalidomide and ch14.18 using the same doses 
and schedules. a Bioluminescence images at day 8 for the different 
groups are shown. b Growth of neuroblastoma tumors. Biolumines-
cence imaging measurements were taken on the left and right sides 
of each mouse and were collected 1, 8, and 15 days after injection 
of tumor cells for calculation of area under the curve (AUC) for each 
group. Data for mice receiving PBMC (two experiments) or PBMC-
NK (one of the two experiments) are shown. PBMC mice that were 
treated with both lenalidomide and ch14.18 had smaller AUC com-
pared to untreated (P < 0.001), lenalidomide alone (P = 0.007), or 
ch14.18 alone (P = 0.011). PBMC-NK mice that were treated with 
both lenalidomide and ch14.18 did not have smaller AUC compared 
to lenalidomide or ch14.18 alone. Tumor growth in mice receiv-
ing PBMC versus PBMC-NK was no different with lenalidomide or 
ch14.18 alone treatment but was less for the PBMC group treated 
with the combination of lenalidomide and ch14.18 (P = 0.006). 
Overall, there was a significant reduction in treatment efficacy as 
measured by AUC with PBMC-NK versus PBMC (P = 0.017). c 
Survival of mice in different groups. Survival time, which is defined 
as the days from tumor cell injection until the mouse is killed due 
to tumor size or the end of the experiment (day 56), was greater for 
PBMC mice that were treated with both lenalidomide and ch14.18 
than for untreated (P < 0.0001), lenalidomide-treated (P < 0.0001) 
or ch14.18-treated (P < 0.0001) groups. PBMC-NK mice that were 
treated with both lenalidomide and ch14.18 survived longer than 
those treated with lenalidomide (P = 0.03) or ch14.18 (P = 0.04) 
alone. Overall, there was a significant reduction in treatment efficacy 
as measured by survival with PBMC-NK versus PBMC (P = 0.048) 
(Supplemental Figure 7). Images in Fig. 6a are from one experiment, 
whereas data in Figs. 6b and c are combined from two experiments
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ch14.18 alone, and survival was no different for lenalido-
mide but was marginally poorer for the NK-depleted group 
and ch14.18 alone-treated group (P = 0.075) (Supplemen-
tal Figure 7). Together, these data indicate that lenalido-
mide enhances survival of mice treated with ch14.18 and 
that this in vivo effect involves NK cells.
Discussion
This study demonstrates the potential immunosuppressive 
impact of neuroblastoma cells interacting with monocytes/
macrophages in the tumor microenvironment upon anti-
tumor cell functions of NK cells alone or combined with 
the anti-neuroblastoma GD2 mAb ch14.18. IL-6, which is 
secreted by mononuclear phagocytes in response to neu-
roblastoma cells, and TGFβ1, which is secreted by both 
tumor cells and mononuclear phagocytes in response to 
neuroblastoma cells, suppress the activation of NK cells 
by IL-2. We show for the first time that lenalidomide, an 
immune-modulating drug that enhances IL-2 activation 
of NK cells, prevents suppressive effects of both IL-6 and 
TGFβ1, likely by inhibiting the induction of their respec-
tive signaling pathways, i.e., STAT3 for IL-6 and SMAD2/3 
for TGFβ1. Maximal suppression of neuroblastoma tumor 
growth in NOD/SCID mice by NK cells in a microenviron-
ment in which tumor cell STAT3 and SMAD2/3 pathways 
are active occurs when mice are treated with both lena-
lidomide and ch14.18. These results suggest that therapy 
with antibodies that mediate ADCC with NK cells may be 
improved by the addition of lenalidomide, which both acti-
vates NK cells and prevents their suppression by IL-6 and 
TGFβ1 in the microenvironment.
We compared gene expression of neuroblastoma tumors 
and cell lines using a TLDA assay and found that tumors 
have higher expression of TAM-associated genes as well 
as of IL-6 and IL-10 than cell lines. TGFβ1 was strongly 
expressed by both tumors and cell lines, suggesting that 
tumor cells are a major source of this cytokine. Expression 
of IFNγ, IL-2, IL-12, and IL-15 was low in both tumors 
and cell lines. Quantifying cytokines released by neuroblas-
toma cell lines and cell line/monocyte co-cultures showed 
that the cytokine profiles of CM from co-cultures were 
similar to the gene expression signature of tumors. These 
data support the conclusion that neuroblastoma tumors are 
rich in cytokines that are potentially immunosuppressive 
(IL-6, IL-10, and TGFβ1) but not in cytokines that support 
NK cell proliferation, differentiation, and activation (IL-2, 
IL-15, IL-12).
Neuroblastoma cell/monocyte co-cultures generated CM 
that contained IL-6 and TGFβ1 and that suppressed IL-2 
activation of NK cells for direct cytotoxicity, ADCC, and 
IFNγ secretion. Depletion of IL-6 and TGFβ1 from CM by 
combining antibodies against both cytokines removed sup-
pression. We discovered that lenalidomide, at a clinically 
achievable concentration [16, 32], prevented the suppres-
sion of IL-2-mediated activation of NK cell cytotoxicity, 
ADCC, and IFNγ secretion by neuroblastoma/monocyte 
CM. Recombinant IL-6 and TGFβ1 were used at function-
ally effective doses to model the neuroblastoma/monocyte 
generated molecules to study the effects of these cytokines 
individually without or with lenalidomide upon NK cell 
activation.
We demonstrated for the first time that IL-6, likely via 
activation of the STAT3 signaling pathway, suppresses IL-2 
induction of human NK cell direct cytotoxicity and ADCC, 
which is accompanied by decreased release of granzymes 
A and B and expression of perforin but not by altered 
expression of NKG2D, DNAM-1, NKp46, and CD16. We 
also show that IL-6, similar to the neuroblastoma/mono-
cyte CM, significantly suppresses release of IFNγ by IL-
2-stimulated NK cells. As with experiments testing neuro-
blastoma/monocyte CM, we discovered that lenalidomide, 
at clinically achievable concentrations [16, 32], prevented 
IL-6 suppression of IL-2-mediated activation of NK cell 
cytotoxicity, ADCC, and IFNγ secretion.
TGFβ1 has previously been shown to suppress, via 
SMAD3, IL-2 activation of NK cells for ADCC and IL-2 
or IL-12 plus CD16 activation for IFNγ secretion [7]. 
TGFβ1 also has been reported to suppress the expres-
sion of NKG2D and CD16 [10–13]. Our data confirm that 
TGFβ1 activates SMAD2/3 and inhibits NK cell expres-
sion of NKG2D and CD16 and mediation of ADCC. We 
extend previous information by showing that the expres-
sion of DNAM-1, NKp46, CD56, CD107a and perforin, 
and the release of granzymes A and B are decreased by 
TGFβ1. IL-2-stimulated NK cell secretion of IFNγ was 
decreased by TGFβ1. Suppression of direct cytotoxicity, 
ADCC, and IFNγ secretion by TGFβ1 was also prevented 
by lenalidomide.
The mechanisms underlying the effects of lenalido-
mide appear to be at least partially due to the inhibition 
of STAT3 and SMAD2/3 phosphorylation by IL-6 and 
TGFβ1, respectively. Lenalidomide has previously been 
reported to inhibit phosphorylation of STAT3 in a multiple 
myeloma cell line, and this was enhanced by the addition 
of simvastatin [33]. However, lenalidomide has not been 
reported to inhibit phosphorylation of STAT3 for any other 
cell type. Attribution of changes in NK cell effector func-
tions to the activation of the STAT3 pathway is supported 
by the observation that genetic ablation of STAT3 in hemat-
opoietic cells of mice bearing B16 melanoma resulted in 
greater cytotoxicity of spleen NK cells compared to those 
from tumor-bearing wild-type mice [6]. Inhibition of the 
phosphorylation of SMAD2/3 by lenalidomide has not 
been previously reported for any cell type. Using STAT3 
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and SMAD2/3 reporter neuroblastoma cells, we showed 
that reporter activity was inhibited when treatment with 
lenalidomide was begun 72 h after injection of tumor cells 
into NOD/SCID mice, which suggest that lenalidomide 
may block ongoing phosphorylation and so contribute to 
a decrease in the level of activation. Although the mecha-
nisms whereby lenalidomide inhibits the activation of these 
pathways remain to be determined, our findings suggest 
that it may enhance the activity of agents that specifically 
target these pathways.
Using a model in which human PBMC and neuro-
blastoma cells are co-injected into NOD/SCID mice, we 
showed that lenalidomide increases the in vivo anti-tumor 
cell activity of mAb ch14.18. Human NK cells appear to 
be the main effectors with combined lenalidomide and 
ch14.18 treatment because tumor growth was less and 
survival was longer for mice receiving PBMC versus NK-
depleted PBMC. Another study that used Raji lymphoma 
cells growing in SCID mice demonstrated that murine 
NK cells can mediate the anti-tumor effect of rituximab 
combined with pomalidomide or lenalidomide [18]. It is 
unlikely that murine NK cells contributed significantly to 
the anti-tumor effect of lenalidomide combined with mAb 
ch14.18 in our experiments since we depleted them from 
NOD/SCID mice with an anti-IL-2Rβ/CD122 mAb [26] 
before neuroblastoma and PBMC co-injection.
Clinical trials of lenalidomide in children and adults 
have demonstrated immunological effects that would be 
expected to enhance ADCC in vivo without the significant 
toxicities observed with the combination of ch14.18, IL-2, 
and GM-CSF [1, 16, 17, 32]. Our preclinical data and the 
immunological effects observed in clinical trials of lena-
lidomide [16, 17] suggest that the combination of lenalido-
mide and ch14.18 will be active against neuroblastoma in 
patients. Of importance, the toxicity of such a regimen may 
be less than the current standard regimen of ch14.18, IL-2, 
and GM-CSF.
In summary, our study demonstrates that the microen-
vironmental milieu of neuroblastoma cells includes IL-6 
and TGFβ1, which suppress IL-2 activation of NK cells for 
direct cytotoxicity, ADCC, and IFNγ secretion. Our finding 
that lenalidomide both enhances activation and overcomes 
the suppression of NK cell anti-tumor functions suggests 
that it may improve efficacy of treatment with anti-tumor 
cell antibodies such as ch14.18.
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